Cyclohexanone Curcumin Analogs May Hinder Progression of Castration-Resistant Prostate Cancer
Posted: Thursday, January 10, 2019
According to research published in Cancer Science, multiple cyclohexanone curcumin analogs were shown to be at least as effective as curcumin (a component of turmeric, a type of ginger) in inhibiting the progression of castration-resistant prostate cancer in vitro and in vivo. In previous clinical trials, curcumin had been studied in treating cancer, but it seemed to have poor bioavailability; thus, more effective alternatives have been sought.
The investigators synthesized four cyclohexanone curcumin analogs and first analyzed their antimetastatic activity on PC3 and PLS10 cells. Analogs 2,6-bis-(4-hydroxy-3-methoxy-benzylidene)-cyclohexanone (2A) and 2,6-bis-(3,4-dihydroxy-benzylidene)-cyclohexanone (2F) showed higher anticancer progression qualities than curcumin. Although analog 2F reduced matrix metalloproteinases (MMP) activities, analog 2A reduced both activities and secretions for MMP-2 and MMP-9.
The most potent of those analogs synthesized, analog 2A then underwent an in vivo study. The compound was similarly effective to curcumin (30 mg/kg body weight) area reduction of lung tumors in mice intravenously injected with PLS10 cells; also like curcumin, the compound was detectable in the serum of mice both 30 minutes and 60 minutes after intraperitoneal injections. Overall, analog 2A proved to be superior to curcumin in inhibiting the growth of PLS10 cells.
“Taken together, we could summarize that analog 2A showed promising activities in inhibiting [castration-resistant prostate cancer] progression, both in vitro and in vivo,” concluded Shugo Suzuki, MD, PhD, of Nagoya City University in Japan, and colleagues.
Disclosure: The study authors’ disclosure information can be found at onlinelibrary.wiley.com.
